CLAIMS

1. A compound of formula I



I

wherein Nu is a heterocyclic nucleus selected from thiazole in which the R_1, R_2 and R_3 substituents are disposed as indicated below



or imidazo[4,5-b]pyridine in which the R_1, R_2 and R_3 substituents are disposed as indicated below



wherein

R_1 is pyrimidyl or pyridyl;

X is $-NR_6-Y-$, -O- or -S-,

where R_6 is H, C_1-C_4alkyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkylC_1-C_3alkyl, C_6-C_{18}aryl, C_3-C_{18}heteroaryl, C_7-C_{19}aralkyl or C_4-C_{19}heteroaralkyl, and -Y- is C_1-C_4alkylene or a direct bond;

R_2 is phenyl, optionally substituted by one or more substituents, each of which is independently selected from

halo,

CF_3,

cyano,

amido or thioamido which is optionally mono- or di-N-substituted by C_1-C_4alkyl or the N atom of which forms a 5-7 membered heterocyclic ring optionally containing an additional hetero atom selected from O, S or N which N is optionally C_1-C_4alkyl C_1-C_4alkylcarbonyl or C_1-C_4alkylthiocarbonyl substitued,

carboxylate or thiocarboxylate optionally in the form of an optionally halo-substituted C_1-C_{10}alkoxy, C_2-C_{10}alkenoxy, C_2-C_{10}alkynoxy, C_3-C_7cyclalkoxy, C_5-C_7cycloalkenoxy, aryloxy, arylalkoxy, heteroaryloxy or heteroarylalkoxy ester,

optionally mono- or di-C_1-C_4alkyl-substituted-C_0-C_1alkyl optionally C_1-C_4alkyl- or C_3-C_5 cycloalkyl-substituted-carbonyl or -thiocarbonyl,

optionally halo-substituted-C_1-C_4alkoxy, C_2-C_4alkenoxy, C_2-C_4alkynoxy, C_3-C_5cycloalkoxy or C_3-C_5cyclothioalkoxy,

optionally halo substituted C_1-C_4 alkyl,

oxycarbonyl or optionally N-C_1-C_4alkyl-substituted aminocarbonyl both of which are optionally C_1-C_4alkyl or C_3-C_5cycloalkyl substituted (including thiocarbonyl analogues thereof),

optionally mono- or di-C_1-C_4alkyl-substituted-C_0-C_1alkylamine which is optionally mono-or di-N-C_1-C_4 alkyl substituted,

optionally mono- or di-C_1-C_4alkyl-substituted-C_0-C_1alkyl optionally N-C_1-C_4alkyl-substituted amino-carbonyl or -thiocarbonyl,

optionally N-C_1-C_4alkyl-substituted amino-sulphinyl or -sulphonyl optionally substituted by

optionally mono- or di-N-C_1-C_4alkyl-substituted amino,

a nitrogen atom which form a heterocyclic ring of 5 to 7 members optionally containing an additional heteroatom selected from O, S or N which N is optionally C_1-C_4alkyl C_1-C_4alkylcarbonyl or C_1-C_4alkylthiocarbonyl substitued, or

sulphinyl or sulphonyl optionally substituted by

optionally halo-substituted-C_1-C_4alkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl,

optionally mono- or di-C_1-C_4alkyl-substituted amino,

a nitrogen atom which form a heterocyclic ring of 5 to 7 members optionally containing an additional heteroatom selected from O, S or N which N is optionally C_1-C_4alkyl C_1-C_4alkylcarbonyl or C_1-C_4alkylthiocarbonyl substitued;

R_3 is H, amino, C_1-C_{10}alkyl, C_3-C_{10}cycloalkyl, C_3-C_{18}heterocycloalkyl, C_6-C_{18}aryl, or C_3-C_{18}heteroaryl each of which is optionally substituted by up to 4 substituents separately selected from C_1-C_4alkyl, halogen, halo-substitued-C_1-C_4alkyl, hydroxy, C_1-C_4alkoxy, C_1-C_4alkylthio, C_6-C_{18}aryl, C_3-C_{18} heteroaryl, C_6-C_{18}arylC_1-C_4alkyl, C_3-C_{18} heteroarylC_1-C_4alkyl, C_3-C_{18}heterocycloalkyl or optionally mono- or di-C_1-C_4alkyl substituted amino or by N-heterocyclyl containing from 5 to 7 ring atoms and optionally a further hetero atom selected from O, S or N, all of which are further optionally substituted halo, hydroxy, C_1-C_4alkyl, C_1-C_4alkoxy or C_1-C_4alkoxycarbonyl;

R_4 is C_1-C_{10}alkyl, C_6-C_{18}aryl, C_3-C_{18}heteroaryl, or C_3-C_{12}cycloalkyl optionally substituted by up to 3 substituents separately selected from C_1-C_4alkyl, halogen, halo-substitued- C_1-C_4alkyl, hydroxy, C_1-C_4alkoxy, C_1-C_4alkylthio, optionally mono- or di-C_1-C_4alkyl substituted amino, or by N-heterocyclyl containing from 5 to 7 ring atoms and optionally containing a further hetero atom selected from O, S or N,

and pharmaceutically-acceptable and -cleavable esters thereof and acid addition salts thereof

2. A compound according to claim 1 of formula II



II

wherein

Z is N or CH;

X is $-NR_6-Y-$, -O- or -S-,

where R_6 is H, C_1-C_4alkyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkylC_1-C_3alkyl, C_6-C_{18}aryl, C_3-C_{18}heteroaryl, C_7-C_{19}aralkyl or C_4-C_{19}heteroaralkyl, and -Y- is C_1-C_4alkylene or a direct bond ;

R_2' is phenyl, optionally substituted by one or more substituents, each of which is independently selected from halo, CF_3, cyano, amido or thioamido, carboxylate or thiocarboxylate, C_1-C_4alkoxy, C_1-C_4alkyl, or NH_2 which is optionally mono-or di-C_1-C_4 alkyl substituted;

R_3' is H, C_1-C_{10}alkyl, C_3-C_{10}cycloalkyl, C_3-C_{18}heterocycloalkyl, C_6-C_{18}aryl, or C_3-C_{18}heteroaryl each of which is optionally substituted by up to 4 substituents separately selected from C_1-C_4alkyl, halogen, halo-substitued-C_1-C_4alkyl, hydroxy, C_1-C_4alkoxy, C_1-C_4alkylthio, or optionally mono-or di-C_1-C_4alkyl substituted amino, or by N-heterocyclyl containing from 5 to 7 ring atoms and optionally containing a further hetero atom selected from O, S or N;

R_4' is C_6-C_{18}aryl, C_3-C_{18}heteroaryl, or C_3-C_{12}cycloalkyl each of which is optionally substituted by up to 4 substituents separately selected from C_{1-4}alkyl, halogen, halo-substitued-C_{1-4}alkyl, hydroxy, C_{1-4}alkoxy, C_{1-4}alkylthio, or optionally mono-or di-C_1-C_4alkyl substituted amino, or by N-heterocyclyl containing from 5 to 7 ring atoms and optionally containing a further hetero atom selected from O, S or N,

and pharmaceutically-acceptable and -cleavable esters thereof and acid addition salts thereof.

3. A compound according to claim 2 of formula II'



II'

wherein

R_4'' is phenyl or C_3-C_7cycloalkyl each of which is optionally mono-substituted by halogen, C_1-C_4alkyl, C_1-C_4alkoxy, hydroxy, trihalomethyl or optionally mono-or di-C_1-C_4alkyl substituted amino, or by N-heterocyclyl containing from 5 to 7 ring atoms and optionally containing a further hetero atom selected from O, S or N;

R_{10} is halogen, cyano, amido, thioamido, amino or C_1-C_4alkyl;

R_3'' is H, C_1-C_4alkyl, phenyl, pyridyl, morpholinyl, piperidyl, piperazyl, or optionally mono- or di-C_{1-4}alkyl substituted amino, each of which is optionally substituted, e.g. by up to 2 substituents, separately selected from C_1-C_4alkyl, halogen, hydroxy, C_1-C_4alkoxy, or optionally mono-or di-C_1-C_4alkyl substituted amino;

Z is N or CH and

X'' is -NH-Y'-, -O- or -S-, where Y' is $-CH_2-$, $-CH_2-CH_2-$, $-CH(CH_3)-$ or a direct bond, and pharmaceutically-acceptable and -cleavable esters thereof and acid addition salts thereof.

4. A compound according to claim 2 selected from:

4-(4-Fluorophenyl)-5-(2-[1-(S)-phenylethyl]amino-4-pyrimidinyl)-2-(4-methyl-piperidine-1-yl)thiazole;

4-(4-Fluorophenyl)-5-(2-[1-(S)-phenylethyl]amino-4-pyrimidinyl)-2-(4-NH-piperidine-1-yl)thiazole;

4-(4-Fluorophenyl)-2-(4-methylpiperidine-1-yl)-5-(2-[cyclopropyl-methyl]amino-4-

pyridinyl)thiazole and

4-(4-Fluorophenyl)-2-(4-NH-piperidine-1-yl)-5-(2-(1-(S)-phenylethyl)amino-4-pyridinyl)thiazole;

and pharmaceutically-acceptable and -cleavable esters thereof and acid addition salts thereof.

5. A process for the preparation of a compound of formula II''



II''

wherein R_3'', R_4'', R_{10} and Z are as defined in claim 3 and X''' is -NH-, which comprises reacting the corresponding precursor compound of formula III or III'



III



III'

with the corresponding R_4''-NH_2 amine, wherein R_3'', R_4'' and R_{10} are as defined in claim 3, and thereafter, if desired, converting the compound of formula II'' obtained into a further compound of formula II'' or a pharmaceutically-acceptable and -cleavable ester thereof or acid addition salt thereof.

6. A compound according to claim 1 of formula V



V

wherein

R_{11} is pyrimidyl;

X is $-NR_6-Y-$, -O- or -S-,

where R_6 is H, C_1-C_4alkyl, C_6-C_{18}aryl, C_3-C_{18}heteroaryl, C_7-C_{19}aralkyl or C_4-C_{19}heteroaralkyl, and -Y- is C_1-C_4alkylene or a direct bond ;

R_{12} is phenyl, optionally substituted by one or more substituents, each of which is independently selected from

halo,

CF_3,

cyano,

amido or thioamido which is optionally mono- or di-N-substituted by C_1-C_4alkyl or the N atom of which forms a 5-7 membered heterocyclic ring optionally containing an additional hetero atom selected from O, S or N which N is optionally C_1-C_4alkyl C_1-C_4alkylcarbonyl or C_1-C_4alkylthiocarbonyl substitued,

carboxylate or thiocarboxylate optionally in the form of an optionally halo-substituted C_1-C_{10}alkoxy, C_2-C_{10}alkenoxy, C_2-C_{10}alkynoxy, C_3-C_7cyclalkoxy, C_5-C_7cycloalkenoxy, aryloxy, arylalkoxy, heteroaryloxy or heteroarylalkoxy ester,

optionally mono- or di-C_1-C_4alkyl-substituted-C_0-C_1alkyl optionally C_1-C_4alkyl- or C_3-C_5cycloalkyl-substituted-carbonyl or -thiocarbonyl,

optionally halo-substituted-C_1-C_4alkoxy, C_2-Calkenoxy, C_2-Calkynoxy, C_3-C_5cycloalkoxy or C_3-C_5cyclothioalkoxy,

optionally halo substituted C_1-C_4 alkyl,

oxycarbonyl or optionally N-C_1-C_4alkyl-substituted aminocarbonyl both of which are optionally C_1-C_4alkyl or C_3-C_5cycloalkyl substituted (including thiocarbonyl analogues thereof),

optionally mono- or di-C_1-C_4alkyl-substituted-C_0-C_1alkylamine which is optionally mono-or di-N-C_1-C_4 alkyl substituted,

optionally mono- or di-C_1-C_4alkyl-substituted-C_0-C_1alkyl optionally N-C_1-C_4alkyl-substituted amino-carbonyl or -thiocarbonyl,

optionally N-C_1-C_4alkyl-substituted amino-sulphinyl or -sulphonyl optionally substituted by

optionally mono- or di-N-C_1-C_4alkyl-substituted amino,

a nitrogen atom which form a heterocyclic ring of 5 to 7 members optionally containing an additional heteroatom selected from O, S or N which N is optionally C_1-C_4alkyl C_1-C_4alkylcarbonyl or C_1-C_4alkylthiocarbonyl substituted, or

sulphinyl or sulphonyl optionally substituted by

optionally halo-substituted-C_1-C_4alkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl,

optionally mono- or di-N-C_1-C_4alkyl-substituted amino,

a nitrogen atom which form a heterocyclic ring of 5 to 7 members optionally containing an additional heteroatom selected from O, S or N which N is optionally C_1-C_4alkyl C_1-C_4alkylcarbonyl or C_1-C_4alkylthiocarbonyl substitued;

R_{13} is H, amino, C_1-C_{10}alkyl, C_3-C_{10}cycloalkyl, C_3-C_{18}heterocycloalkyl, C_6-C_{18}aryl, or C_3-C_{18}heteroaryl all optionally substituted by up to 4 substituents separately selected from C_1-C_4alkyl, halogen, halo-substitued-C_1-C_4alkyl, hydroxy, C_1-C_4alkoxy, C_1-C_4alkylthio, C_6-C_{18}aryl, C_3-C_{18}heteroaryl, C_6-C_{18}arylC_1-C_4alkyl, C_3-C_{18}heteroarylC_1-C_4alkyl, C_3-C_{18}heterocycloalkyl or optionally mono- or di-N-C_1-C_4alkyl substituted amino all of which are optionally substituted by halo, hydroxy, C_1-C_4alkyl, C_1-C_4alkoxy or C_1-C_4alkoxycarbonyl;

R_{14} is C_1-C_{10}alkyl, C_6-C_{18}aryl, C_3-C_{18}heteroaryl, or C_3-C_{12}cycloalkyl optionally substituted by up to 3 substituents separately selected from C_1-C_4alkyl, halogen, halo-substitued-C_1-C_4alkyl, hydroxy, C_1-C_4alkoxy, C_1-C_4alkylthio, optionally mono- or di-N-C_1-C_4alkyl substituted amino, or by N-heterocyclyl containing from 5 to 7 ring atoms and optionally containing a further hetero atom selected from O, S or N,

and pharmaceutically-acceptable and -cleavable esters thereof and acid addition salts thereof.

7. A compound according to claim 6 of formula V'



V'

wherein

R_{14}' is phenyl or C_3-C_7cycloalkyl each of which is optionally mono-substituted by halogen, C_1-C_4alkyl, C_1-C_4alkoxy, hydroxy, trihalomethyl optionally mono- or di-N-C_1-C_4alkyl substituted amino, or by N-heterocyclyl containing from 5 to 7 ring atoms and optionally containing a further hetero atom selected from O, S or N;

R_{10} is halogen, CF_3, C_1-C_4alkyl or C_1-C_4alkoxy;

R_{13}' is pyridyl, pyrimidyl, piperazinyl, piperidinyl, NR_9R_{10}, $-CH_2OH$, $CH_2NR_{15}R_{16}$, $-CH_2CH_2R_{15}R_{16}$, or Het-C_1-C_4alkyl-,

wherein

R_9 and R_{10} are separately selected from H, C_1-C_4alkyl, C_6-C_{18}aryl, C_3-C_{18} heteroaryl, C_6-C_{18}arylC_1-C_4alkyl, C_3-C_{18}heteroarylC_1-C_4alkyl all of which are optionally substituted by halo, hydroxy, C_1-C_4alkyl, C_1-C_4alkoxy, C_1-C_4alkoxycarbonyl,

R_{11} and R_{12} are separately selected from H or C_1-C_6alkyl, and

Het is N-heterocyclyl containing from 5 to 7 ring atoms and optionally containing a further hetero atom (e.g. O,S or N)

X'' is -NH-Y'-, -O- or -S-, where Y' is $-CH_2-$, $-CH_2-CH_2-$, $-CH(CH_3)-$ or a direct bond, and pharmaceutically-acceptable and -cleavable esters thereof and acid addition salts thereof.

8. A compound according to claim 6 selected from:

2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(piperidino-N-2-ethyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(N,N-diethylamino-N-2-ethyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(morpholino-N-2-ethyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(isopropylamino-N-2-ethyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(pyrrolidino-N-2-ethyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(3-pyridyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(4-pyridyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-(1-(S)-phenylethyl)amino-4-pyrimidinyl)-5-aminoimidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-aminoimidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-(1-(S)-phenylethyl)amino-4-pyrimidinyl)-5-(4-NH-1-piperazinyl) imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(4-NH-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclobutylamino-4-pyrimidinyl)-5-(4-NH-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopropylamino-4-pyrimidinyl)-5-(4-NH-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-(1-(S)-phenylethyl)amino -4-pyrimidinyl)-5-(4-methyl-1-piperazinyl) imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(4-methyl-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclobutylamino-4-pyrimidinyl)-5-(4-methyl-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopropylamino-4-pyrimidinyl)-5-(4-methyl-1-piperazinyl)imidazo[4,5-b]pyridine;

2-(4-Fluorophenyl)-1-(2-(1-(S)-phenylethyl)amino-4-pyrimidinyl)-5-(4-(2-hydroxy-2-methyl)propyl-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(4-(2-hydroxy-2-methyl)propyl-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclobutylamino-4-pyrimidinyl)-5-(4-(2-hydroxy-2-methyl)propyl-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopropylamino-4-pyrimidinyl)-5-(4-(2-hydroxy-2-methyl)propyl-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(4-piperidinyl) imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(1-methyl-4-piperidinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(1-(2-hydroxy-2-methyl)propyl-4-piperidinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(benzylamino) imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(morpholino) imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(3-fluorophenyl amino)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(pyridyl-4-amino)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(1-ethoxycarbonyl piperidine-4-amino)imidazo[4,5-b]pyridine, and
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(piperidine-4-amino)imidazo[4,5b]pyridine.

9. A process for the production of

(i) an Agent of the Invention of formula V"



V"

wherein R_{11}, R_{12}, R_{14} and X are as previously defined and R_{13}" is $-CH_2-CH_2NR_{15}R_{16}$ or $-CH_2-CH_2$-Het wherein R_{15}, R_{16} and Het are as previously defined comprising reacting a corresponding vinyl precursor of formula VI



VI

wherein R_{11}, R_{12}, R_{14} and X are as previously defined with the corresponding amine of formula $HNR_{15}R_{16}$ or N-heterocycloalkyl ring compound;

(ii) an Agent of the Invention of formula V wherein R_{13} is aryl or heteroaryl comprising arylation or heteroarylation of a compound of formula VII



VII

wherein R_{11}, R_{12}, R_{14} and X are as previously defined;

(iii) an Agent of the Invention of formula V wherein R_{13} is -N-heterocycloalkyl, -NH-aryl, -NH-heteroaryl, -NH-heterocycloalkyl, -NH-(C_1-C_4alkyl)-heterocycloalkyl, -NH-(C_1-C_4alkyl)-aryl, -NH-(C_1-C_4alkyl)-heteroaryl, or -NH-(C_1-C_4alkyl)-heterocycloalkyl comprising

coupling a corresponding chloroprecursor compound of formula VII, as defined above, with the corresponding N-heterocycloalkyl compound or amine;

(iv) an Agent of the Invention of formula V in which R_{13} is $-NH_2$, comprising reacting the corresponding methyl sulphinyl compound of formula VIII'



VIII'

wherein R_{11}, and R_{12} are as previously defined, with the corresponding amine of formula R_{14}-NH_2, and

(v) an Agent of the Invention of formula V in which R_{13} is piperazinyl , comprising reacting a corresponding methylsulphinyl compound of formula VIII"



VIII"

wherein R_{11} and R_{12} are as previously defined and P is an N protecting group, with the corresponding amine of formula R_{14}-NH_2.

10. A method of inhibiting production of soluble TNF, especially TNFα, or of reducing inflammation in a subject (i.e., a mammal, especially a human) in need of such treatment which method comprises administering to said subject an effective amount of a compound according to claim 1.

11. A compound according to claim 1 for use as a pharmaceutical, e.g. for use as an immunosuppressant or antiinflammatory agent or for use in the prevention, amelioration or treatment of any disease or condition as described above, e.g., an autoimmune or inflammatory disease or condition.

12. A pharmaceutical composition comprising a compound according to claim 1 in association with a pharmaceutically acceptable diluent or carrier, e.g., for use as an immunosuppressant or anti-inflammatory agent or for use in the prevention, amelioration or treatment of any disease or condition as described above, e.g., an autoimmune or inflammatory disease or condition.

13. Use of a compound according to claim 1 in the manufacture of a medicament for use as an immunosuppressant or anti-inflammatory agent or for use in the prevention, amelioration or treatment of any disease or condition as described above, e.g., an autoimmune or inflammatory disease or condition.